RT Journal Article
SR Electronic
T1 Diagnostic and Prognostic Value of <sup>11</sup>C-Methionine PET for Nonenhancing Gliomas
JF American Journal of Neuroradiology
JO Am. J. Neuroradiol.
FD American Society of Neuroradiology
SP 44
OP 50
DO 10.3174/ajnr.A4460
VO 37
IS 1
A1 K. Takano
A1 M. Kinoshita
A1 H. Arita
A1 Y. Okita
A1 Y. Chiba
A1 N. Kagawa
A1 Y. Fujimoto
A1 H. Kishima
A1 Y. Kanemura
A1 M. Nonaka
A1 S. Nakajima
A1 E. Shimosegawa
A1 J. Hatazawa
A1 N. Hashimoto
A1 T. Yoshimine
YR 2016
UL http://www.ajnr.org/content/37/1/44.abstract
AB BACKGROUND AND PURPOSE: Noninvasive radiologic evaluation of glioma can facilitate correct diagnosis and detection of malignant transformation. Although positron-emission tomography is considered valuable in the care of patients with gliomas, 18F-fluorodeoxyglucose and 11C-methionine have reportedly shown ambiguous results in terms of grading and prognostication. The present study compared the diagnostic and prognostic capabilities of diffusion tensor imaging, FDG, and 11C-methionine PET in nonenhancing gliomas.MATERIALS AND METHODS: Thirty-five consecutive newly diagnosed, histologically confirmed nonenhancing gliomas that underwent both FDG and 11C-methionine PET were retrospectively investigated (23 grade II and 12 grade III gliomas). Apparent diffusion coefficient, fractional anisotropy, and tumor-to-normal tissue ratios of both FDG and 11C-methionine PET were compared between grade II and III gliomas. Prognostic values of these parameters were also tested by using progression-free survival.RESULTS: Grade III gliomas showed significantly higher average tumor-to-normal tissue and maximum tumor2-to-normal tissue than grade II gliomas in 11C-methionine (P = .013, P = .0017, respectively), but not in FDG-PET imaging. There was no significant difference in average ADC, minimum ADC, average fractional anisotropy, and maximum fractional anisotropy. 11C-methionine PET maximum tumor-to-normal tissue ratio of 2.0 was most suitable for detecting grade III gliomas among nonenhancing gliomas (sensitivity, 83.3%; specificity, 73.9%). Among patients not receiving any adjuvant therapy, median progression-free survival was 64.2 ± 7.2 months in patients with maximum tumor-to-normal tissue ratio of &lt;2.0 for 11C-methionine PET and 18.6 ± 6.9 months in patients with maximum tumor-to-normal tissue ratio of &gt;2.0 (P = .0044).CONCLUSIONS: 11C-methionine PET holds promise for World Health Organization grading and could offer a prognostic imaging biomarker for nonenhancing gliomas.MET11C-methioninePFSprogression-free survivalT/Ntumor-to-normal tissueT/Naveaverage tumor-to-normal tissueT/Nmaxmaximum tumor-to-normal tissue